Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Revance Therapeutics, Inc. Clear all
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

NCT02565732
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

NCT03911102
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • Sarasota, Florida • Itasca, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001, Vehicle Comparator
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

NCT02706795
View directory record Official record
Conditions
Torticollis (Spasmodic)
Interventions
DaxibotulinumtoxinA
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Fountain Valley, California • Colorado Springs, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01064518
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo (Dose B)
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

NCT02580370
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 6, 2026, 10:13 AM EDT
Terminated Phase 3 Interventional

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01818076
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

NCT03821402
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 6, 2026, 10:13 AM EDT
Not listed No phase listed Observational

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

NCT06154070
View directory record Official record
Conditions
Migraine Disorders
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

NCT03786770
View directory record Official record
Conditions
Frown Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boca Raton, Florida • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 6, 2026, 10:13 AM EDT
Not listed No phase listed Observational

Open Label, 6-month Study for High Frequency and Chronic Migraine,

NCT06133491
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Daxibotulinumtonix A
Biological
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT03137407
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Botulinum Toxins, Type A, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Duluth, Georgia • Des Plaines, Illinois • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01776606
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014635
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

NCT04259086
View directory record Official record
Conditions
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Interventions
DaxibotulinumtoxinA for injection
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Manhattan Beach, California • San Diego, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

NCT03608397
View directory record Official record
Conditions
Cervical Dystonia
Interventions
DaxibotulinumtoxinA for injection, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00907387
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
RT001, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991
View directory record Official record
Conditions
Skin Aging
Interventions
Placebo, Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 6, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
Other · Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

NCT06411002
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
DAXXIFY
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 6, 2026, 10:13 AM EDT